Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2003; 41:879-888, doi:10.1016/S0735-1097(03)00081-0
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pagani, F. D.
Right arrow Articles by Aaronson, K. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pagani, F. D.
Right arrow Articles by Aaronson, K. D.

Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans

Histological analysis of cell survival and differentiation

Francis D. Pagani, MD, PhD, FACC*,*, Harout DerSimonian, PhD, Agatha Zawadzka, MS, Kristie Wetzel, BS, Albert S. B. Edge, PhD, Douglas B. Jacoby, PhD, Jonathan H. Dinsmore, PhD, Susan Wright, BS, RN*, Tom H. Aretz, MD{ddagger}, Howard J. Eisen, MD§ and Keith D. Aaronson, MD, MPH{dagger}

* Section of Cardiac Surgery, University of Michigan, Ann Arbor, MI, USA
{dagger} Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
{ddagger} Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
§ Temple University, Philadelphia, Pennsylvania, USA
Diacrin, Inc., Charlestown, Massachusetts, USA



View larger version (92K):

[in a new window]
 
Figure 1 Human skeletal myoblast expansion and purity. A shows the anti-CD56 staining profile of the final myoblast product implanted to Patient 2 using flow cytometry. B (10x) and C (4x) show the myoblast cells in culture during expansion. D (10x) and E (4x) show the potential of these cells to fuse and form multinucleated myotubes in an in vitro assay. Some of these multinucleated myotubes are highlighted with arrows in D.

 


View larger version (148K):

[in a new window]
 
Figure 2 Representative trichrome and MY-32 stain of grafted skeletal myoblasts. A shows an area of the graft in a section stained with trichrome. B shows an adjacent section that was stained with the skeletal myosin specific MY-32 antibody. The transplant derived myofibers can be identified by the red staining in trichrome and the dark blue staining in the MY-32 stain. Asterisks (*) mark areas of host myocardial fibers. Scale bar = 50 µm.

 


View larger version (65K):

[in a new window]
 
Figure 3 Representative trichrome and MY-32 stain of grafted skeletal myoblasts. A and B show an area of the graft in a section stained with trichrome at two magnifications. In A, the myotubes can be clearly identified, and in B the higher magnification shows the presence of striated myofibers in some myotubes. C shows an adjacent section that was stained with the skeletal myosin specific MY-32 antibody.

 


View larger version (122K):

[in a new window]
 
Figure 4 Skeletal fast and slow twitch myosin. Shown are surviving skeletal myofibers in the heart from Patient 5 stained with trichrome (A and B), skeletal-specific fast myosin MY-32 (identification of fast twitch skeletal muscle myosin isoforms only) (C) and myosin heavy chain beta slow (D). A, C, and D show adjacent sections from the same graft site, and B shows a different graft site from the same patient, but where the myofibers can be seen in a longitudinal profile. Grafted skeletal myofibers have a distinct stain by trichrome that are marked by stars in B, and the alignment between grafted myofibers and host myofibers is striking. The area of the graft is marked by the dotted line in A, C, and D and individual skeletal myofibers that stained with slow myosin and not fast myosin (MY-32, C) are marked by arrowheads. All images were shot at the same magnification.

 


View larger version (131K):

[in a new window]
 
Figure 5 Representative CD-3 staining of a graft site. The micrograph shows a graft site stained with an antibody to CD-3 to stain immune cells. Some scattered macrophages can be identified in and around the graft site. Some of the macrophages can be seen in association with an area of the containing giant cells. There is no collection of infiltrating immune cells at the graft site to indicate any ongoing immune reaction. The dotted line demarcates an area of viable myocardium. The stars highlight the area with giant cells. Arrows mark the surviving transplanted muscle cells, and the arrowheads mark the CD-3 positive macrophages.

 


View larger version (132K):

[in a new window]
 
Figure 6 Trichrome staining of a graft site demonstrating the presence of giant cells. A and B show an area adjacent to the grafted cells where giant cells have formed. The boxed area in A is shown at higher magnification in B. Multinucleated giant cells are associated with refractile material (arrows), probably plastic that was introduced with the cells. Note that the area of engrafted cells is free from any giant cells.

 


View larger version (68K):

[in a new window]
 
Figure 7 Representative CD-31 staining of a graft site. An antibody to human CD-31 was used to stain graft sections. A shows a representative micrograph in the area of the graft. The dotted line demarcates the border area between the transplant and the adjacent scar. Note the enhanced area of CD-31 staining within the engrafted section. B shows the results from quantitative counts to compare the number of CD-31 vessels at the graft (white bar) and in the adjacent scar (gray bar). Scale bar = 100 µm.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement